News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADMA Biologics, Inc. Reports 2012 Year End Financial and Operational Results



3/7/2013 6:19:51 AM

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported financial and operational results for the year ended December 31, 2012. Year-end and subsequent highlights include:

•Secured $6 million term loan to advance Phase III study
• Executed long-term manufacturing, supply and license agreement for RI-002

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES